Fig. 3.

CEP based on incremental costs and QALYs in the base-case analysis for the a low-dose and b high-dose comparison, and in the scenario analysis for the c low-dose and d high-dose comparison. a In the semaglutide 0.5 mg vs. dulaglutide 0.75 mg comparison, at a WTP threshold of CAN$50,000, 66% of ICERs were cost effective. b In the semaglutide 1.0 mg vs. dulaglutide 1.5 mg comparison, at a WTP threshold of CAN$50,000, 73% of ICERs were cost effective. c In the semaglutide 0.5 mg vs. dulaglutide 0.75 mg comparison, at a WTP threshold of CAN$50,000, 98% of ICERs were cost effective. d In the semaglutide 1.0 mg vs. dulaglutide 1.5 mg comparison, at a WTP threshold of CAN$50,000, 98% of ICERs were cost effective. CAN$ Canadian dollars, CEP cost-effectiveness plane, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, WTP willingness to pay